Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib for Biochemical Relapse in Prostate Cancer
NCT04635059Phase 2
Key facts
- Status
- Terminated
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Countries
- 1
- Sponsor
- Medical College of Wisconsin
- Modality
- Small Molecules
- Drugs
- pacritinib
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in prostate cancer (PCa), sponsored by Medical College of Wisconsin. Primary endpoint: Six-month PSA Progression-free Survival at 6 months. Started Jun 2021; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Pacritinib
Pacritinib 200 mg BID
03
Endpoints
Primary
Six-month PSA Progression-free Survival
Secondary
PSA Levels
Testosterone Measurement
Beyond the preview
Go deeper on NCT04635059.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635059.